• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Movano Inc. (Amendment)

    4/9/24 5:41:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email
    SC 13G/A 1 ea0203585-13ga1tamkin_movano.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Movano, Inc.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    62459M107

     

    (CUSIP Number)

     

    April 4, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

    (Continued on following pages)

     

     

     

     

     

     

    CUSIP No. 62459M107

     

    1

    NAME OF REPORTING PERSONS

     

    Gregory Tamkin

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐
    (b)
     ☐

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

      18,437
    6

    SHARED VOTING POWER

     

      7,506,084 (1)
    7

    SOLE DISPOSITIVE POWER

     

      18,437
    8

    SHARED DISPOSITIVE POWER

     

    7,506,084 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,524,521

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.66%(2)

    12 TYPE OF REPORTING PERSON

    IN

     

    (1)Consists of 7,506,084 shares of Common Stock held by Leabman Holdings LLC (“Leabman Holdings”). DvineWave Irrevocable Trust dated December 12, 2012 (“DvineWave”) is the sole member and manager of Leabman Holdings. The Reporting Person is co-trustee of DvineWave and shares voting and dispositive power with respect to all securities held by Leabman Holdings.
    (2) Based on the 98,203,068 shares of Common Stock outstanding as of April 8, 2024.

       

    2

     

     

    CUSIP No. 62459M107

     

    1

    NAME OF REPORTING PERSONS

     

    Dorsey & Whitney Trust Company LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐
    (b)
     ☐

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

      0
    6

    SHARED VOTING POWER

     

     

    7,506,084 (1)

    7

    SOLE DISPOSITIVE POWER

     

      0
    8

    SHARED DISPOSITIVE POWER

     

    7,506,084 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,506,084 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.64%(2)

    12 TYPE OF REPORTING PERSON

    OO

      

    (1)Consists of 7,506,084 shares of Common Stock held by Leabman Holdings. DvineWave is the sole member and manager of Leabman Holdings. The Reporting Person is co-trustee of DvineWave and shares voting and dispositive power with respect to all securities held by Leabman Holdings.

    (2)Based on the 98,203,068 shares of Common Stock outstanding as of April 8, 2024.

     

    3

     

     

    CUSIP No. 62459M107

     

    1

    NAME OF REPORTING PERSONS

     

    DvineWave Irrevocable Trust dated December 12, 2012

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐
    (b)
     ☐

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

      7,506,084 (1)
    6

    SHARED VOTING POWER

     

      0
    7

    SOLE DISPOSITIVE POWER

     

      7,506,084 (1)
    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,506,084 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.64%(2)

    12 TYPE OF REPORTING PERSON

    OO

     

    (1)Consists of 7,506,084 shares of Common Stock held by Leabman Holdings. The Reporting Person is the sole member and manager of Leabman Holdings.

    (2)Based on the 98,203,068 shares of Common Stock outstanding as of April 8, 2024.

     

    4

     

     

    Item 4. Ownership.

     

    (a)Amount beneficially owned: See responses to Item 9 on the attached cover pages.

     

    (b)Percent of class: See responses to Item 11 on the attached cover pages.

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to direct the vote: See responses to Item 5 on the attached cover pages.

     

    (ii)Shared power to direct the vote: See responses to Item 6 on the attached cover pages.

     

    (iii)Sole power to dispose or to direct the disposition of: See responses to Item 7 on the attached cover pages.

     

    (iv)Shared power to dispose or to direct the disposition of: See responses to Item 8 on the attached cover pages.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11. 

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 9, 2024

     

      /s/ Gregory Tamkin
      Name: Gregory Tamkin
       
      DORSEY & WHITNEY TRUST COMPANY LLC
       
      /s/ Carl A. Schmidtman
      Name: Carl A. Schmidtman
      Title: President
       
      DVINEWAVE IRREVOCABLE TRUST DTD DECEMBER 12, 2012
       
      /s/ Carl A. Schmidtman
      Name: Carl A. Schmidtman
      Title: President

     

    [Signature page to Schedule 13G]

     

    6

     

     

    INDEX TO EXHIBITS

     

    99.1 Joint Filing Agreement

     

    7

     

    Get the next $MOVE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    Financials

    Live finance-specific insights

    See more
    • Movano Health Reports Q3 2024 Financial Results and Provides Business Update

      Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto

      11/14/24 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health Reports Q2 2024 Financial Results and Provides Business Update

      Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device

      8/14/24 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health Provides Progress Update on EvieMED Regulatory Filing

      Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco

      8/5/24 9:00:00 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MOVE
    SEC Filings

    See more
    • Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

      PLEASANTON, Calif., May 23, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on May 15, 2025.

      5/23/25 4:05:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health's Board of Directors Initiates Process to Maximize Shareholder Value

      PLEASANTON, Calif., May 16, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, announced today that its Board of Directors has initiated a process to explore strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value.  To support this process, Movano Health's Board of Directors has engaged Aquilo Partners as its financial advisor and K&L Gates LLP as its legal counsel. There can be no assurance that this process will result in any transaction or other strategic change or as to the

      5/16/25 4:30:00 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements

      Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device PLEASANTON, Calif., April 22, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wea

      4/22/25 8:00:00 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Caballero Ruben was granted 43,605 shares, increasing direct ownership by 816% to 48,952 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:14 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CFO Cogan Jeremy was granted 62,986 shares, increasing direct ownership by 121% to 115,028 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Mastrototaro John was granted 77,521 shares, increasing direct ownership by 399% to 96,964 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      5/13/25 4:30:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Movano Inc. (0001734750) (Filer)

      5/23/25 4:05:24 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form NT 10-Q filed by Movano Inc.

      NT 10-Q - Movano Inc. (0001734750) (Filer)

      5/21/25 5:22:02 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Movano Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

      8-K - Movano Inc. (0001734750) (Filer)

      5/19/25 8:48:13 AM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/12/24 4:30:19 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/4/24 5:30:08 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

      4 - Movano Inc. (0001734750) (Issuer)

      4/4/24 5:30:14 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Movano Inc.

      SC 13G - Movano Inc. (0001734750) (Subject)

      4/10/24 4:39:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Movano Inc. (Amendment)

      SC 13G/A - Movano Inc. (0001734750) (Subject)

      4/9/24 5:41:12 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Movano Inc.

      SC 13G - Movano Inc. (0001734750) (Subject)

      2/4/22 4:20:05 PM ET
      $MOVE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care